Nephromag (Buffered Phosphate Solution | Mertiatide)

Buffered Phosphate Solution, the active ingredient in Nephromag, is a sterile intravenous solution presented as a buffered phosphate formulation for intravenous use. It is employed in clinical settings to help manage phosphate balance in patients requiring electrolyte support.

GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide, adhering to EU quality standards and providing regulatory documentation for cross‑border distribution.

Nephromag (Buffered Phosphate Solution) is used in medical contexts where phosphate homeostasis is a concern.

Hypophosphatemia: Restores plasma phosphate levels in patients with low serum phosphate. Renal replacement therapy: Maintains phosphate balance during dialysis or continuous renal replacement procedures. Peri‑operative care: Prevents phosphate depletion associated with major surgery or intensive care stays.

Nephromag may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site discomfort: Mild pain or irritation at the infusion site. - Transient hyperphosphatemia: Temporary elevation of serum phosphate levels. - Hypocalcemia: Reduced calcium levels due to phosphate binding. - Nausea: Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hyperphosphatemia: Can lead to calcium‑phosphate precipitation and organ dysfunction. - Allergic reaction: Rash, itching, or anaphylaxis in susceptible individuals. - Cardiovascular instability: Hypotension or arrhythmia during rapid infusion.

When using Nephromag, clinicians should observe several precautionary measures to ensure patient safety.

Baseline assessment: Measure serum phosphate before infusion. Calcium monitoring: Check calcium levels to avoid hypocalcemia. Renal function: Adjust dosing in patients with impaired kidney function. Cardiovascular status: Use cautiously in patients with cardiac disease. Pregnancy and lactation: Safety not established; weigh risks and benefits. Store at ambient temperature: Keep in original container, protect from light and moisture.

Nephromag can interact with other agents that affect mineral balance or renal handling of electrolytes.

Major Interactions (Avoid): - Calcium‑containing products: Co‑administration may cause precipitation of calcium‑phosphate complexes. - Aluminum‑containing antacids: Can bind phosphate and reduce its bioavailability.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: May increase intestinal phosphate absorption. - Loop diuretics: May alter electrolyte balance, requiring monitoring. - ACE inhibitors: Potential impact on renal phosphate handling, warranting observation.